KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

Employees

133

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-06-10	2,268.00 ¥	0.00%	2,700
26-06-09	2,268.00 ¥	0.00%	1,200
26-06-08	2,268.00 ¥	0.00%	600
26-06-05	2,268.00 ¥	-0.04%	1,100
26-06-03	2,269.00 ¥	+0.22%	1,200

Delayed Quote Japan Exchange

More quotes

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-10 EDT			5-day change	1st Jan Change
2,268.00 ^JPY	0.00%		-0.04%	+78.44%

04-22	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
03-24	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI

Market Cap	1.14B 7.08M 6.14M 5.66M 5.3M 9.91M 678M 10.12M 67.52M 26.14M 327M 26.56M 25.99M	P/E Ratio 2009	3.96x	P/E Ratio 2010	13.8x
Enterprise Value	2.04B 12.74M 11.05M 10.19M 9.55M 17.84M 1.22B 18.21M 122M 47.06M 588M 47.82M 46.79M	EV / Sales 2009	0.43x	EV / Sales 2010	0.55x
Free-Float	3.88%	Yield 2009	2.68%	Yield 2010	2.38%

04-22	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
03-24	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI
02-09	Denka Company Limited proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders for ¥7.9 billion.	CI
02-08	Denka Unit Launches Tender Offer for Kainos Laboratories	MT
02-06	Denka Co Ltd - Will launch tender offer for Kainos shares	RE
24-12-18	Italian stationery maker FILA cuts stake in listed Indian unit DOMS	RE
22-03-13	KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	CI
22-02-24	KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	CI
21-11-25	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.	CI
21-11-25	KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.	CI
21-11-25	KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.	CI
21-11-24	KAINOS Laboratories, Inc. authorizes a Buyback Plan.	CI
20-11-25	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.	CI

1 week	-0.04%
Current month	+0.18%
1 month	-0.22%
3 months	-0.40%
6 months	+79.29%
Current year	+78.44%

KAINOS Laboratories, Inc. Stock

Stocks

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Valuation: KAINOS Laboratories, Inc.

Chart: KAINOS Laboratories, Inc.

Latest news : KAINOS Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: KAINOS Laboratories, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 week	2,268	2,269
1 month	2,263	2,277
Current year	1,257	2,284
1 year	1,204	2,284
3 years	1,005	2,284
5 years	929	2,284
10 years	488	2,284

Manager	Title	Age	Since
Yukihiro Nagatsu PSD	President	66	2022-03-31
Tsukasa Hayashi ADM	Chief Administrative Officer	64	2016-05-31
Nobuaki Nakano PRN	Corporate Officer/Principal	62	2024-06-30

Director	Title	Age	Since
Yukihiro Nagatsu BRD	Director/Board Member	66	2014-05-31
Tsukasa Hayashi BRD	Director/Board Member	64	2014-05-31
Kenji Kikuchi BRD	Director/Board Member	74	2014-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAINOS LABORATORIES, INC.	0.00%	-0.04%	+83.35%	+124.78%	62.89M
GUARDANT HEALTH, INC.	+0.15%	-1.62%	+166.98%	+276.91%	17.33B
BIOMÉRIEUX	-1.71%	-2.61%	-43.48%	-24.36%	9.56B
LANTHEUS HOLDINGS, INC.	+4.07%	+1.46%	+29.19%	+24.22%	6.53B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+3.35%	-1.69%	-31.63%	-24.44%	4.91B
CARIS LIFE SCIENCES, INC.	+4.90%	+4.17%	-	-	4.85B
DIASORIN S.P.A.	-2.25%	+1.84%	-27.97%	-29.18%	4.29B
ANDON HEALTH CO., LTD.	-4.99%	-20.03%	+64.03%	+50.59%	4.01B
10X GENOMICS, INC.	-0.21%	-13.28%	+169.48%	-47.99%	3.7B
AUTOBIO DIAGNOSTICS CO., LTD.	+2.20%	+0.16%	-20.38%	-42.78%	2.56B
Average	+0.55%	-0.69%	+43.28%	+34.19%	5.78B
Weighted average by Cap.	+0.49%	+0.31%	+60.99%	+83.15%

	2009	2010
Net sales	3.59B 22.4M 19.44M 17.92M 16.79M 31.37M 2.14B 32.02M 214M 82.76M 1.03B 84.09M 82.28M	4.22B 26.26M 22.79M 21.01M 19.69M 36.78M 2.51B 37.55M 251M 97.03M 1.21B 98.6M 96.47M
Net income	168M 1.05M 907K 836K 783K 1.46M 100M 1.49M 9.97M 3.86M 48.24M 3.92M 3.84M	101M 632K 549K 506K 474K 885K 60.53M 904K 6.03M 2.34M 29.17M 2.37M 2.32M
Net Debt	893M 5.56M 4.83M 4.45M 4.17M 7.79M 533M 7.95M 53.09M 20.55M 257M 20.89M 20.44M	909M 5.66M 4.91M 4.53M 4.24M 7.93M 542M 8.1M 54.04M 20.92M 261M 21.26M 20.8M